Treatment with PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia Lowers Plasma Levels of Platelet-Activating Factor and Its Precursors: A Combined Metabolomic and Lipidomic Approach

Introduction: Familial hypercholesterolemia (FH) is characterized by extremely high levels of circulating low-density lipoprotein cholesterol (LDL-C) and is caused by mutations of genes involved in LDL-C metabolism, including LDL receptor (LDLR), apolipoprotein B (APOB), or proprotein convertase sub...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Alessandro Di Minno, Roberta Clara Orsini, Mattia Chiesa, Viviana Cavalca, Ilenia Calcaterra, Maria Tripaldella, Andrea Anesi, Susanna Fiorelli, Sonia Eligini, Gualtiero I. Colombo, Elena Tremoli, Benedetta Porro, Matteo Nicola Dario Di Minno
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	MDPI AG 2021-08-01
Schriftenreihe:	Biomedicines
Schlagworte:	PCSK9 untargeted metabolomics familial hypercholesterolemia
Online-Zugang:	https://www.mdpi.com/2227-9059/9/8/1073
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!